![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Physiology and Pharmacology, City University of New York Medical School, New York, New York (K.K.); Division of Cancer Prevention, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York (S.B., J.L.W., J.C., J.G., A.G., B.R.); and NicOx S. A., Sophia, Antipolis, France (F.B., P.d.S.).
NO-donating aspirin (NO-ASA), a novel pharmacological agent currently undergoing clinical testing, consists of ASA to which a nitrate group is covalently linked via a spacer molecule. We synthesized the three positional isomers of NO-ASA with respect to the –CH2ONO2 group (ortho, meta, and para) and examined whether this isomerism affects the biological activity of NO-ASA on HT-29 human colon cancer cells. The ortho- and para-isomers showed similar IC50 values (1–5 µM) for cell growth inhibition over 72 h, whereas the IC50 of the meta-isomer was 200 to 500 µM. The ortho- and para-isomers inhibited cell proliferation more potently than the meta-isomer. All three induced apoptosis but the ortho- and para-isomers also induced atypical cells (they maintain their shape but have diminished or absent nuclear material). Treatment for 3 weeks of Min (Apcmin/+) mice, a model of intestinal cancer, with equimolar amounts of meta- and para-NO-ASA decreased the number of tumors in the small intestine by 36 and 59% (P < 0.01), respectively, compared with vehicle-treated controls, thus confirming their in vitro differences in potency. A structure-activity study of the three isomers revealed that substituting an aliphatic for the aromatic spacer or removing the –ONO2 group profoundly diminished NO-ASA's ability to inhibit cell growth, whereas removal of the acetyl group on the ASA moiety did not affect cell growth inhibition. Thus, positional isomerism is critical for the pharmacological properties of NO-ASA against colon cancer and it should be taken into consideration in rational drug design.
Address correspondence to: Dr. Basil Rigas, Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794-8160. E-mail: basil.rigas{at}sunysb.edu
This article has been cited by other articles:
|
|
 |
|
  V. V. Mihaleva, H. A. Verhoeven, R. C. H. de Vos, R. D. Hall, and R. C. H. J. van Ham Automated procedure for candidate compound selection in GC-MS metabolomics based on prediction of Kovats retention index Bioinformatics, March 15, 2009; 25(6): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhao, G. G. Mackenzie, O. T. Murray, Z. Zhang, and B. Rigas Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect Carcinogenesis, March 1, 2009; 30(3): 512 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sun, J. Chen, and B. Rigas Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death Carcinogenesis, January 1, 2009; 30(1): 93 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Hagos, S. O. Abdul-Hay, J. Sohn, P. D. Edirisinghe, R. E. P. Chandrasena, Z. Wang, Q. Li, and G. R. J. Thatcher Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention Mol. Pharmacol., November 1, 2008; 74(5): 1381 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ouyang, J. L. Williams, and B. Rigas NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts Carcinogenesis, September 1, 2008; 29(9): 1794 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Williams, P. Ji, N. Ouyang, X. Liu, and B. Rigas NO-donating aspirin inhibits the activation of NF-{kappa}B in human cancer cell lines and Min mice Carcinogenesis, February 1, 2008; 29(2): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Hagos, R. E. Carroll, T. Kouznetsova, Q. Li, V. Toader, P. A. Fernandez, S. M. Swanson, and G. R.J. Thatcher Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo Mol. Cancer Ther., August 1, 2007; 6(8): 2230 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gao, K. Kashfi, X. Liu, and B. Rigas NO-donating aspirin induces phase II enzymes in vitro and in vivo Carcinogenesis, April 1, 2006; 27(4): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Turchi Nitric oxide and cisplatin resistance: NO easy answers PNAS, March 21, 2006; 103(12): 4337 - 4338. [Full Text] [PDF]
|
|
|
|
|
|
N. Ouyang, J. L. Williams, and B. Rigas NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR){delta} expression in APCmin/+ mice proportionally to their tumor inhibitory effect: Implications for the role of PPAR{delta} in carcinogenesis Carcinogenesis, February 1, 2006; 27(2): 232 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Hundley and B. Rigas Nitric Oxide-Donating Aspirin Inhibits Colon Cancer Cell Growth via Mitogen-Activated Protein Kinase Activation J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goel, C. Gasche, and C. R. Boland Chemoprevention Goes Gourmet: Different Flavors of NO-Aspirin Mol. Interv., August 1, 2005; 5(4): 207 - 210. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
